Sahm Adrangi's Kerrisdale Capital Issues Negative Report on Proteostasis Therapeutics, Inc., and Announces Conference-Call Schedule

NEW YORK, March 20, 2018 /PRNewswire/ -- Kerrisdale Capital, a private investment manager, has published a negative report explaining its short position in Proteostasis Therapeutics, Inc. PTI, a development-stage biopharmaceutical company whose market value is based primarily on PTI-428, its lead drug candidate for the treatment of cystic fibrosis. Proteostasis's stock price increased ~100% after the FDA granted the drug Breakthrough Therapy and Orphan Drug designations, but Kerrisdale's analysis demonstrates that PTI-428 is likely ineffective. Kerrisdale also details a pattern of low-quality data and troubling omissions in Proteostasis's public disclosures.

The full report can be found at http://kerr.co/pti.

Kerrisdale has a short position in Proteostasis Therapeutics, Inc., and stands to benefit if its share price falls.

Conference Call Schedule
Kerrisdale will host a conference call on Tuesday, March 20 at 10:30am ET to discuss the Proteostasis report.

To participate in the conference call, dial (866) 834-3313 (United States) or (409) 981-0700 (international) and reference the Kerrisdale Capital call.

About Kerrisdale Capital
Kerrisdale Capital Management, LLC, is a fundamentally-oriented investment manager that focuses on long-term value investments and event-driven special situations.

Contact
Agnes Cao
Kerrisdale Capital
acao@kerrisdalecap.com 
212-257-4385

Kerrisdale Capital Management, LLC is a member of the Financial Industry Regulatory Authority, CRD number 160804.

View original content:http://www.prnewswire.com/news-releases/sahm-adrangis-kerrisdale-capital-issues-negative-report-on-proteostasis-therapeutics-inc-and-announces-conference-call-schedule-300616553.html

SOURCE Kerrisdale Capital Management, LLC